A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
21/09/2021at 15:35

New Johnson & Johnson data show high booster shot effectiveness

Data from a phase III trial demonstrate a 94-percent protection against Covid-19 with a Johnson & Johnson booster shot.
Photo: Jens Dresling
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

An additional dose of Johnson & Johnson's Covid-19 vaccine has shown an effectiveness of 94 percent, the company just announced in the published results of a phase III trial.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • The European Medicines Agency's Amsterdam headquarters | Photo: Rob Acket/EMA

    EMA begins assessment of Pfizer booster application

    For subscribers

  • Danish Minister of Health Magnus Heunicke | Photo: Jens Dresling

    Denmark sells 500,000 surplus vaccines to New Zealand

    For subscribers

  • Danish government cancels vaccine production tender

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
  • Novo Nordisk doubles obesity sales in 2022
  • New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Further reading

Foto: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Foto: Novo Nordisk / PR
Pharma & biotech

Novo Nordisk wins case in US appeals court

Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

For subscribers

Latest news

  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
See all

Jobs

  • Commercial Director

  • Regulatory Affairs Professional

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Application Manager

  • Application Manager

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Commercial Director

  • Regulatory Affairs Professional

  • Clinical Operational Associate

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Application Manager

  • Application Manager

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge